



## **IMAGION BIOSYSTEMS LIMITED**

**(ASX: IBX)**

13 July 2020

### **Imagion to work with Boston University on next generation imaging technology**

MELBOURNE — Imagination Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has become a member of the Nanosystems Engineering Research Center at Boston University, where researchers are developing ultrasensitive magnetic sensors that could greatly simplify the MagSense™ detection system. If successful, the new sensors could enable the use of MagSense cancer detection technology in a doctor's suite in addition to a hospital imaging suite.

The Center, funded by the US National Science Foundation (NSF), is developing next generation cellular metamaterials technologies with a primary focus on advancing nano-bio-manufacturing methods. Membership provides Imagination with priority access to the new technologies and intellectual property being developed at the Center. Of specific interest to Imagination is the Center's advancements in the use of Micro-Electro-Mechanical systems (MEMs) as ultrasensitive magnetometers which may have application in detecting cardiovascular events and bio-medical imaging. MEMs are ubiquitous in everyday technologies such as cellular phones and gaming devices providing functionality such as accelerometers, gyroscopes and even in microphones. For Imagination, MEMs-based sensors could significantly reduce the size and cost of the MagSense system by eliminating the requirement of using cryogenically cooled sensors, making it both more affordable and portable like ultrasound equipment used in a doctor's office.

"We are very excited by the research being done at Boston University on super small highly sensitive magnetic sensors," said Bob Proulx, Executive Chairman of Imagination Biosystems. "Historically, we have focused on using known technologies like superconducting quantum interference devices, so-called SQUIDs, because they are proven technologies. Having visibility and access to cutting-edge innovative technologies through our membership with the Center could enable us to produce imaging systems that don't need cryogenic cooling and are more versatile, expanding the commercial opportunity for our MagSense system."

"We are pleased to welcome Imagination Biosystems to the Center," said Dr. David Bishop, Head of the Division of Materials Science and Engineering at Boston University and Director of the Center. "We are always keen to have industry partners as members to help focus our research projects on practical applications that can translate from academic research to commercial value. We see Imagination's MagSense technology as being a good match and look forward to collaborating with them."

#### **About the Nanosystems Engineering Research Center**

Officially known as the Nanosystems Engineering Research Center for Directed Multiscale Assembly of Cellular Metamaterials with Nanoscale Precision (CELL-MET), the Center, led by Boston University, was established to leverage the financial support provided by the National Science Foundation in creating opportunities for public and private collaboration in research and development of new nanoscale technologies. Industry and academic members of the Center provide input to research projects prioritized by the Center and have priority access to inventions for research and commercial purposes.

#### **About Imagination Biosystems**

Imagination Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagination Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

**-ENDS**



For further information please visit [www.imagionbiosystems.com](http://www.imagionbiosystems.com)

This Announcement has been approved by the Disclosure Committee of Imagion Biosystems Limited.

**U.S. Media Contact:**

Matthew Wygant

[matthew@biotechwriting.com](mailto:matthew@biotechwriting.com)

+1-408-905-7630

**Australian Media & Investor Relations:**

Kyahn Williamson, WE Communications

[We-AUImagionBiosystems@we-worldwide.com](mailto:We-AUImagionBiosystems@we-worldwide.com)

+61 (0) 401018828